OXFORD, United Kingdom, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC) today announced its financial results for the third quarter ended September 30, 2022 and provided an overview of the Company’s recent corporate developments. Vaccitech is a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious diseases, autoimmunity, and cancer.
“This has been a very exciting quarter at Vaccitech. During the past three months we have made significant progress on our clinical programs, strengthened our balance sheet and leadership team, and continued to actively engage with investors,” remarked Bill Enright, CEO of Vaccitech. “We dosed the first patient in our Phase 2b clinical trial of VTP-300 in HBV and reported the findings of our Phase 1b/2a study of VTP-300 at the American Association for the Study of Liver Disease (AASLD) Liver meeting. In addition, we published a paper in Cell showing the activation of two key pathways with intravenous (IV) vaccination of a SNAPvax construct, which led to improved T cell mediated tumor killing in a pre-clinical model. We were also very pleased to announce the promotion of Gemma Brown to the role of CFO. I would also like to note that that this quarter’s royalty and milestone payments from the sales of Vaxzervria®, AstraZeneca’s COVID-19 vaccine, have assisted in extending our cash runway into the first quarter of 2025. All told, this was a very active quarter for us, and we look forward to continuing our progress and outreach in the coming quarter and year.”
“We have made excellent progress in our clinical programs in the past quarter and expect to reach a number of important clinical milestones in 2023,” stated Dr. Meg Marshall, Chief Medical Officer of Vaccitech. “We expect to have initiated our Phase 1/2a clinical study in the fourth quarter of 2022 with the first patient first visit (FPFV) for VTP-850, our prostate cancer program, early in the first quarter of 2023, and FPFV for VTP-1100, our HPV-Cancer program, early in the third quarter of next year. FPFV for VTP-1000, our program in Celiac disease, is slated for the fourth quarter of 2023. We also plan to present data from multiple ongoing studies of VTP-300 in HBV next year as well. So, we are looking forward to a 2023 filled with exciting clinical advances.”
Third Quarter 2022 Financial Highlights
- Cash position: As of September 30, 2022, cash and cash equivalents were $200.1 million, compared to $214.1 million as of December 31, 2021. The cash burn from operating activities was $43.9 million, being the net of R&D and G&A spend offset by the cash received from revenue recognized in respect of sales of Vaxzevria®. $5.2 million of net cash was used in investing activities, which includes the buildout of the state of the art laboratory and Corporate Headquarters in Harwell, United Kingdom, where the Company relocated in the third quarter of 2022.
- Revenues: Revenues comprised primarily of the Company’s share of milestone and royalty payments received by OUI from AstraZeneca related to commercial sales of Vaxzevria®. Revenues were $6.2 million in the third quarter of 2022 compared to $17.1 million in the second quarter of 2022, with the reduction attributable to no milestones being achieved in the third quarter of 2022.
- Research and development expenses: Research and development expenses were $9.7 million in the third quarter of 2022 compared to $9.7 million in the second quarter of 2022, showing consistent total spend as we continue to advance our pipeline. The quarter on quarter R&D expense per program is outlined in the following table.
| three months ended September 30, 2022 | three months ended June 30, 2022 | Change | ||||
| $000 | $000 | $000 | ||||
| Direct research and development expenses by program: | ||||||
| VTP-200 HPV | 1,310 | 804 | 506 | |||
| VTP-300 HBV | 2,418 | 4,361 | - 1,943 | |||
| VTP-600 NSCLC1 | 111 | 77 | 34 | |||
| VTP-800/850 Prostate cancer | 1,160 | 460 | 700 | |||
| Other and earlier stage programs | 1,687 | 1,508 | 179 | |||
| Total direct research and development expenses | 6,686 | 7,210 | - 524 | |||
| Internal research and development expenses: | ||||||
| Personnel-related (including share-based compensation) | 2,626 | 2,197 | 429 | |||
| Facility related | 308 | 240 | 68 | |||
| Other internal costs | 124 | 73 | 51 | |||
| Total research and development expense | 9,744 | 9,720 | 24 | |||
1 The VTP-600 NSCLC Phase 1/2a trial is sponsored by Cancer Research UK
- General and administrative expenses: General and administrative expenses were a gain of $11.1 million (after including a foreign exchange gain of $18.7 million) in the third quarter of 2022, compared to a gain of $6.4 million (after including a foreign exchange gain of $15.2 million) in the second quarter of 2022. Excluding the foreign exchange gain, G&A expenses were $7.6 million in the third quarter of 2022, which were mainly attributable to personnel expenses of $2.8 million, including the share-based payment charge of $0.6 million, insurance costs of $1.5 million, and legal and professional fees of $2.3 million. Excluding the foreign exchange gain, G&A expenses for the second quarter were $8.8 million and were mainly attributable to personnel expenses of $4.3 million, including the share-based payment charge of $2.1 million, insurance costs of $1.6 million, and legal and professional fees of $1.0 million.
- Net Income: For the third quarter of 2022, the Company generated a net income attributable to its shareholders of $8.2 million, or $0.22 both per fully diluted share and per basic share, compared to a net income attributable to shareholders of $15.7 million, or $0.41 per fully diluted share and $0.42 per basic share, for the second quarter of 2022.
Recent Corporate Developments
Clinical developments:
- On October 31, 2022, we announced the dosing of the first patient in HBV003, a phase 2b clinical trial of VTP-300 to evaluate the optimal timing of low dose nivolumab and impact of additional doses of the MVA boost for a sustained decline in HBsAG.
Pre-clinical developments:
- On October 27, 2022, we announced the publication of research from VTP-1100 in Cell that demonstrates anti-tumor activity achieved with intravenous (IV) vaccination of a SNAPvax construct in an animal model. The study demonstrates that IV administration of SNAPvax primes and expands antigen-specific T cells and reverses suppression in the tumor microenvironment, which promotes T cell infiltration and tumor cell killing. An Investigational New Drug (IND) application submission is expected during the first half of 2023 for HPV related cancer.
- On November 7, 2022 Dr. Young-Suk Lim, Professor of Gastroenterology in the Liver Center at University of Ulsan College of Medicine, presented a poster reporting Phase 1b/2a clinical trial data on VTP-300 at AASLD. The poster presentation showed VTP-300 immunotherapy, as monotherapy and when combined with low dose nivolumab at the boosting time point, was immunogenic and showed a sustained reduction in HBsAg in well-controlled CHB patients, and was administered with no treatment related SAEs and infrequent transient transaminitis. Two of five patients dosed in cohort 3 (ChAdOx1-HBV + MVA-HBV with low dose nivolumab given at the boost) with starting HBsAg levels below 100 achieved non-detectable levels of surface antigen at the data cutoff.
Company Leadership:
- On September 20, 2022, we announced the promotion of Gemma Brown to Chief Financial Officer.
Upcoming Milestones
- In addition to the recent developments detailed above, in the fourth quarter of 2022 the Company expects to
- Open a Phase 1/2 clinical trial of VTP-850 in patients with prostate cancer
- In the first quarter of 2023, the Company
- Intends to conduct an interim efficacy review of HPV001, a Phase 1b/2 clinical trial of VTP-200, a potential treatment for low grade HPV-related cervical lesions
- Expects to have FPFV for VTP-850 in our prostate cancer program
- Intends to move its U.S. team into a new, state of the art facility in Germantown, Maryland
- In 2023, the Company expects to
- Submit IND applications for its two lead SNAPvax candidates, VTP-1000 for the treatment of celiac disease and VTP-1100 for the treatment of HPV-associated cancers
- Have FPFV for VTP-1100 in our HPV cancer program
- Have FPFV for VTP-1000 in our Celiac disease program
- Present data from multiple ongoing clinical studies at AASLD and The European Association for the Study of the Liver (EASL) conferences
About Vaccitech
Vaccitech plc (“the Company”) is a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines for the treatment of chronic infectious diseases, cancer, autoimmunity, and other diseases where the T cell arm of the immune system is believed to play an important role. The company’s proprietary platforms include modified simian adenoviral vectors (ChAdOx1 and ChAdOx2), other viral vectors including the well-validated Modified vaccinia Ankara (MVA), and synthetic nano-particle technologies (SNAPvax™ and Syntholytic™). The combination of different technologies in a mix and match approach (heterologous prime-boost) consistently generates significantly higher magnitudes of T cells compared with other technologies and approaches. The Company has a broad pipeline of both clinical and preclinical stage therapeutic programs to treat solid tumors, chronic viral infections as well as additional prophylactic viral vaccine programs. Vaccitech co-invented a COVID-19 vaccine, Vaxzevria®, with the University of Oxford, now approved for use in many territories and exclusively licensed worldwide to AstraZeneca through OUI. Vaccitech is entitled to receive a share of all milestone and royalty income received by OUI from AstraZeneca related to Vaxzevria®.
Forward Looking Statements
This press release contains forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, which can generally be identified as such by use of the words “would,” “forward,” “expect,” “plan,” “intend,” “believe,” “potential,” “continue,” and similar expressions, although not all forward-looking statements contain these identifying words. These forward looking statements include express or implied statements regarding the Company’s future expectations, plans and prospects, and include, without limitation, statements regarding the timing and advancement of the Company’s programs, including the clinical trials of VTP-200, VTP-300, and VTP-850, statements regarding the timing for the initiation of dosing of VTP-300, VTP-850, and the Company’s two lead SNAPvax candidates, VTP-1000 and VTP-1100, statements regarding the timing for the potential IND applications for VTP-1000 and VTP-1100, statements regarding the presentation of data at future conferences, and statements regarding the Company’s capital. Any forward-looking statements in this press release are based on management’s current expectations and beliefs and are subject to numerous risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, risks and uncertainties related to: the success, cost and timing of the Company’s product development activities and planned and ongoing clinical trials, the Company’s ability to execute on its strategy, regulatory developments, the Company’s ability to fund its operations, global economic uncertainty and the impact that the current ongoing COVID-19 pandemic will have on the Company’s clinical trials, preclinical studies and access to capital and other risks identified in the Company’s filings with the Securities and Exchange Commission (the “SEC”), including its Annual Report on Form 10-K for the year ended December 31, 2021, its Quarterly Report on Form 10-Q for the second quarter of 2022 and subsequent filings with the SEC. The Company cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. The Company expressly disclaims any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements.
VACCITECH PLC
CONDENSED CONSOLIDATED BALANCE SHEETS
(IN THOUSANDS, EXCEPT NUMBER OF SHARES AND PER SHARE AMOUNTS)
(UNAUDITED)
| September 30, 2022 | December 31, 2021 | |||||||||||
| ASSETS | ||||||||||||
| Current assets: | ||||||||||||
| Cash and cash equivalents | $ | 200,104 | $ | 214,054 | ||||||||
| Accounts receivable | 26 | 20 | ||||||||||
| Accounts receivable - related parties | 6,152 | - | ||||||||||
| Research and development incentives receivable | 4,091 | 6,229 | ||||||||||
| Prepaid expenses and other current assets | 8,248 | 6,462 | ||||||||||
| Total current assets | 218,621 | 226,765 | ||||||||||
| Goodwill | 12,630 | 12,630 | ||||||||||
| Property and equipment, net | 6,766 | 1,829 | ||||||||||
| Intangible assets, net | 29,059 | 31,430 | ||||||||||
| Right of use assets, net | 7,558 | 7,257 | ||||||||||
| Other assets | 847 | 804 | ||||||||||
| Total assets | $ | 275,481 | $ | 280,715 | ||||||||
| LIABILITIES AND SHAREHOLDERS’ EQUITY | ||||||||||||
| Current liabilities: | ||||||||||||
| Accounts payable | $ | 2,411 | $ | 2,419 | ||||||||
| Accrued expenses and other current liabilities | 11,323 | 7,875 | ||||||||||
| Deferred revenue | 111 | 182 | ||||||||||
| Operating lease liability – current | 186 | 523 | ||||||||||
| Debt | - | 159 | ||||||||||
| Total current liabilities | 14,031 | 11,158 | ||||||||||
| Operating lease liability – non current | 8,071 | 6,540 | ||||||||||
| Contingent consideration | 2,836 | 2,371 | ||||||||||
| Deferred tax liability, net | 5,680 | 8,084 | ||||||||||
| Other non-current liabilities | 711 | - | ||||||||||
| Total liabilities | $ | 31,329 | $ | 28,153 | ||||||||
| Commitments and contingencies | ||||||||||||
| Shareholders’ equity: | ||||||||||||
| Ordinary shares, £0.000025 nominal value; 37,291,492 shares authorized, issued and outstanding (December 31, 2021: authorized, issued and outstanding: 37,188,730) | 1 | 1 | ||||||||||
| Deferred A shares, £1 nominal value; 63,443 shares authorized, issued and outstanding (December 31, 2021: authorized, issued and outstanding: 63,443) | 86 | 86 | ||||||||||
| Deferred B shares, £0.01 nominal value; 570,987 shares authorized, issued and outstanding (December 31, 2021: authorized, issued and outstanding: 570,987) | 8 | 8 | ||||||||||
| Deferred C shares, £0.000007 nominal value, 27,828,231 shares authorized, issued and outstanding (December 31, 2021: authorized, issued and outstanding: 27,828,231) | 01 | 01 | ||||||||||
| Additional paid-in capital | 376,939 | 369,103 | ||||||||||
| Accumulated deficit | (82,054 | ) | (108,585 | ) | ||||||||
| Accumulated other comprehensive loss – foreign currency translation adjustments | (51,143 | ) | (8,488 | ) | ||||||||
| Total shareholders’ equity attributable to Vaccitech plc shareholders’ | 243,837 | 252,125 | ||||||||||
| Noncontrolling interest | 315 | 437 | ||||||||||
| Total shareholders’ equity | $ | 244,152 | $ | 252,562 | ||||||||
| Total liabilities and shareholders’ equity | $ | 275,481 | $ | 280,715 | ||||||||
1 indicates amount less than thousand
VACCITECH PLC
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
(IN THOUSANDS, EXCEPT NUMBER OF SHARES AND PER SHARE AMOUNTS)
(UNAUDITED)
| Three months ended | Nine months ended | |||||||||||||
| September 30, 2022 | September 30, 2021 | September 30, 2022 | September 30, 2021 | |||||||||||
| License revenue 1 | $ | 6,165 | 16 | 38,237 | 48 | |||||||||
| Service revenue | - | - | - | 21 | ||||||||||
| Research grants and contracts | - | 3 | 9 | 200 | ||||||||||
| Total revenue | 6,165 | 19 | 38,246 | 269 | ||||||||||
| Operating expenses | ||||||||||||||
| Research and development | 9,744 | 4,371 | 30,165 | 13,490 | ||||||||||
| General and administrative | (11,132 | ) | 1,184 | (13,914 | ) | 15,332 | ||||||||
| Total operating expenses | 1,388 | 5.555 | 16,251 | 28,822 | ||||||||||
| Income/ (loss) from operations | 7,553 | (5,536 | ) | 21,995 | (28,553 | ) | ||||||||
| Other income (expense): | ||||||||||||||
| Change in fair value of derivatives embedded in convertible loan notes | - | - | - | 5,994 | ||||||||||
| Change in fair value of contingent consideration | (317 | ) | - | (943 | ) | - | ||||||||
| Unrealized exchange gain on convertible loan notes | - | - | - | 209 | ||||||||||
| Loss on extinguishment of convertible loan notes | - | - | - | (13,789 | ) | |||||||||
| Interest income | 1,024 | - | 1,776 | 2 | ||||||||||
| Interest expense | 11 | - | 3 | (2,650 | ) | |||||||||
| Research and development incentives | (724 | ) | 959 | 1,150 | 2,789 | |||||||||
| Other | - | - | 51 | (3 | ) | |||||||||
| Total other (expense)/ income | (6 | ) | 959 | 2,037 | (7,448 | ) | ||||||||
| Tax benefit | 674 | 7 | 2,452 | 60 | ||||||||||
| Net income/(loss) | 8,221 | (4,570 | ) | 26,484 | (35,941 | ) | ||||||||
| Net loss attributable to noncontrolling interest | 21 | 13 | 47 | 189 | ||||||||||
| Net income/(loss) attributable to Vaccitech plc shareholders | 8,242 | (4,557 | ) | 26,531 | (35,752 | ) | ||||||||
| Weighted-average ordinary shares outstanding, basic | 37,247,123 | 34,843,154 | 37,213,787 | 22,697,462 | ||||||||||
| Weighted-average ordinary shares outstanding, diluted | 38,156,564 | 34,843,154 | 38,226,092 | 22,697,462 | ||||||||||
| Net income/(loss) per share attributable to ordinary shareholders, basic | $ | 0.22 | (0.13 | ) | 0.71 | (1.58 | ) | |||||||
| Net income/(loss) per share attributable to ordinary shareholders, diluted | $ | 0.22 | (0.13 | ) | 0.69 | (1.58 | ) | |||||||
| Net income/(loss) | $ | 8,221 | (4,570 | ) | 26,484 | (35,941 | ) | |||||||
| Other comprehensive loss – foreign currency translation adjustments | (19.940 | ) | (6,473 | ) | (42,730 | ) | (7,803 | ) | ||||||
| Comprehensive loss | (11,719 | ) | (11,043 | ) | (16,246 | ) | (43,744 | ) | ||||||
| Comprehensive loss attributable to noncontrolling interest | 51 | 25 | 122 | 194 | ||||||||||
| Comprehensive loss attributable to Vaccitech plc shareholders | $ | (11,668 | ) | (11,018 | ) | (16,124 | ) | (43,550 | ) | |||||
1Includes license revenue from related parties for the three and nine month periods ended September 30, 2022, of $6.2 million and $38.2 million, respectively.
| IR contacts: | |
| Christopher M. Calabrese | Kevin Gardner |
| Managing Director | Managing Director |
| LifeSci Advisors | LifeSci Advisors |
| 917-680-5608 | 617-283-2856 |
| ccalabrese@lifesciadvisors.com | kgardner@lifesciadvisors.com |
| Media contact: | |
| Mike Beyer | |
| SAM BROWN, INC | |
| 312-961-2502 | |
| mikebeyer@sambrown.com | |
| Company contact: | |
| Jonothan Blackbourn | |
| IR & PR Manager | |
| Vaccitech | |
| IR@vaccitech.co.uk |
